Clinical Trials Logo

Gemcitabine clinical trials

View clinical trials related to Gemcitabine.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06374914 Not yet recruiting - Bladder Cancer Clinical Trials

Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients

Start date: April 9, 2024
Phase:
Study type: Observational

Studies in the literature are limited both throughout Turkey and in general. For this reason, as a result of the study that we will create, it will provide us with information for bladder protective treatments in patients who do not respond to BCG therapy in bladder cancer patients.

NCT ID: NCT05647330 Not yet recruiting - Lung Neoplasms Clinical Trials

Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer

Start date: December 15, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of hydroxychloroquine (600mgBID) combined with gemcitabine (1000mg/m2,d1,8) in the third-line and above treatment of advanced NSCLC.

NCT ID: NCT05487443 Not yet recruiting - Clinical trials for Biliary Tract Cancer

The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies

Start date: August 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To the patient of terminal biliary malignancy tumor, how should the patient's treatment plan choose ? To address this problem, this study intends to analyze systemic venous gemcitabine-based chemotherapy regimen combined with immune checkpoint inhibitors in patients with advanced BTC, to evaluate the long-term efficacy and toxicity of patients, and to search for predictable biomarkers. In order to clarify the advantages and disadvantages of intravenous chemotherapy combined with immunotherapy for patients with advanced biliary malignancy, provide certain basis for clinical work, and then select the most suitable treatment plan for patients according to the different characteristics of individual patients.

NCT ID: NCT05030077 Not yet recruiting - Clinical trials for Urothelial Carcinoma

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to VEGFR, FGFR, PDGFR and c-Kit. This study intends to assess the efficacy and safety of anlotinib combined with platinum/gemcitabine for first line treatment of advanced urothelial carcinoma.